Kaitlyn Kosko

DocwireNews

The first in-human study of datopotamab deruxtecan (Dato-DXd) showed the optimal dose for greater tumor response, PFS, and safety to be 6&thinsp;mg/kg every 3 weeks compared with two other dosing regimens.The phase 1 study evaluated three doses for patients with metastatic NSCLC: 4 mg/kg (n=50), 6 mg/kg (n=50), or 8&thinsp;mg/kg (n=80). The maximum tolerated dose (MTD) was found to be 8 mg/kg.Tumor size was measured at screening, every 6&thinsp;weeks up to week 36, and then every 12&thinsp;weeks while patients remained on Dato-DXd.The 6-mg/kg dose was identified by Yasong Lu, MD, and colleagues as the optimal dose for patients because it was more tolerable than the MTD and more efficacious than Dato-DXd 4 mg/kg. Lower rates of interstitial lung disease were seen in the 6-mg/kg cohort than in the 8-mg/kg cohort (8% vs 15%, respectively). Moreover, patients in the 6-mg/kg cohort also experienced less stomatitis and mucosal inflammation compared with patients in the 8-mg/kg cohort.Once the 8-mg/kg dose was stopped over safety concerns, analyses of the 6-mg/kg and 4-mg/kg doses showed that Dato-DXd 6 mg/kg provided a better mean objective response rate than Dato-DXd 4 mg/kg (23.8% vs 18.6%, respectively). The mean hazard ratio of PFS was 0.74.Because Dato-DXd 6 mg/kg demonstrated an optimal benefit-risk profile, the researchers recommended this dose for late-phase development.

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Optimal Datopotamab Deruxtecan Dose for Patients With Metastatic NSCLC

Non-Small Cell Lung Cancer

The first in-human study of datopotamab deruxtecan showed the optimal dose for treating NSCLC.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe